Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibilityNikolaos A. Patsopoulos, Efthimios Dardiotis, Sergio E. Baranzini et al.|Science|2019Cited by 1.4k
Clinical Relevance of Brain Volume Measures in Multiple SclerosisNicola De Stefano, Bernd C. Kieseier, Laura Airas et al.|CNS Drugs|2014Cited by 293
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple SclerosisTim Spelman, Jan Lycke, Melinda Magyari et al.|JAMA Neurology|2021Cited by 237
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis RiskMitja Mitrovič, Nadia Barizzone, Nikolaos A. Patsopoulos et al.|Cell|2018Cited by 172
Initial high-efficacy disease-modifying therapy in multiple sclerosisMathias Due Buron, Melinda Magyari, Thor Ameri Chalmer et al.|Neurology|2020Cited by 160